Keratoconjunctivitis Sicca (Dry Eye) Report H2 2018 - Review of 41 Companies & Drug Profiles - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 24, 2018--The “Keratoconjunctivitis Sicca (Dry Eye) - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Keratoconjunctivitis Sicca (Dry Eye) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 8, 31, 5, 1, 32, 4 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:Introduction Keratoconjunctivitis Sicca (Dry Eye) - Overview Keratoconjunctivitis Sicca (Dry Eye) - Therapeutics Development Keratoconjunctivitis Sicca (Dry Eye) - Therapeutics Assessment Keratoconjunctivitis Sicca (Dry Eye) - Companies Involved in Therapeutics Development Keratoconjunctivitis Sicca (Dry Eye) - Drug Profiles Keratoconjunctivitis Sicca (Dry Eye) - Dormant Projects Keratoconjunctivitis Sicca (Dry Eye) - Discontinued Products Keratoconjunctivitis Sicca (Dry Eye) - Product Development Milestones Appendix
Companies MentionedAldeyra Therapeutics Inc Allergan Plc Ascendia Pharmaceuticals LLC Aurinia Pharmaceuticals Inc BioLineRx Ltd Cambium Medical Technologies LLC Clementia Pharmaceuticals Inc Dompe Farmaceutici SpA HanAll Biopharma Co Ltd Huons Global Co Ltd Icure Pharmaceutical Inc Kala Pharmaceuticals Inc Kukje Pharmaceutical Industry Co Ltd Kv1.3 Therapeutics Laboratoires Thea SA Laboratorios Sophia SA de CV Lee’s Pharmaceutical Holdings Ltd Merck & Co Inc Mitotech SA Nanomerics Ltd Nemus Bioscience Inc Novaliq GmbH Ocular Therapeutix Inc Oculis ehf Ocunova LLC OncoNOx ApS Otsuka Holdings Co Ltd Palatin Technologies Inc Pharmaleads SA Quorum Innovations LLC Redwood Pharma AB RegeneRx Biopharmaceuticals Inc Santen Pharmaceutical Co Ltd Senju Pharmaceutical Co Ltd Shire Plc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/3wvd5k/keratoconjunctivit?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180924005354/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Optical Disorders Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/24/2018 04:53 AM/DISC: 09/24/2018 04:53 AM